QuidelOrtho (QDEL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.13
- Estimate
- -$0.05
- Surprise
- +374.6%
- Revenue (period 2026-06-28)
- $630.9M
- Score today
- 5.5/10
Revenue source: xbrl.
How the report landed
QuidelOrtho (QDEL) beat the -$0.05 estimate with adjusted EPS of $0.13 — a large 374.6% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates QDEL Sell at 5.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +374.6% surprise compares with a +86.5% four-quarter average. Next scheduled report: 2027-02-10.
What argues against it
- Concentration risk — Supplier: single and sole source suppliers
- Target reached (-0.1% upside)
- Quality below floor (2.8 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.48
- Stop
- $11.61
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
QDEL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $984.1M
- P/E (fwd)
- 10.1
- 52-week range
- $9.92–$35.58
- Off 52-week high
- 64.9%
- RSI (14)
- 47
- Volume vs avg
- 0.92×
- Score today
- 5.5/10